Roelof Rongen
Chief Executive Officer & Board Director Adolore BioTherapeutics
Mr. Rongen is a serial entrepreneur and R&D / Commercial Development leader with extensive experience across many therapeutic areas and functions. He is the CEO of Adolore BioTherapeutics (Gene Therapy for Chronic Pain) and Co-Founder of AeirBio (Solid Tumor Therapies). He founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB); and he was integral to the development and commercialization of multiple blockbuster products such as Humira® and Lovaza®. Mr. Rongen holds a Graduate Engineering degree in Molecular Sciences/Biotechnology from Wageningen University in the Netherlands, and an MBA from the Kellogg School of Management at Northwestern University
Seminars
- Understanding what drives interest and what’s driving hesitation across the field
- Discussing the role of policy, regulation, and public trust in shaping long-term investment
- Reviewing the various sources of funding that exist for companies beyond VCs
- Understanding how payers evaluate value when multiple therapies exist for the same disease
- Learning how coverage decisions, rebates, and clinical trade-offs impact pricing outcomes
- Exploring how to align internal teams on pricing strategy early to avoid reimbursement delays and maximize launch success
- Understanding how payers evaluate value when multiple therapies exist for the same disease
- Learning how coverage decisions, rebates, and clinical trade-offs impact pricing outcomes
- Exploring how to align internal teams on pricing strategy early to avoid reimbursement delays and maximize launch success
